

Revision date: 13-Jul-2011 Version: 3.0 Page 1 of 8

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc **Pfizer Pharmaceuticals Group** 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com Pfizer Ltd Ramsgate Road Sandwich, Kent **CT13 9NJ United Kingdom** +00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Material Name: DIFLUCAN® (Fluconazole) capsules

DIFLUCAN®, DIFLU; FLUCAN; FUNGATA; FUNGUSTATIN; TRICAN; TRIFLUCAN; ZOLTEC Trade Name:

Chemical Family: Synthetic class of compounds known as bis-triazoles Intended Use: Pharmaceutical product used as antifungal agent.

2. HAZARDS IDENTIFICATION

White capsules Appearance: Signal Word: WARNING

Harmful if swallowed. Statement of Hazard:

> Suspected of damaging the unborn child. May cause harm to breastfed babies.

Additional Hazard Information:

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on : liver.

Rare cases of serious liver damage and allergic reactions have been reported .

Known Clinical Effects: Adverse effects associated with therapeutic use include skin rash, headache, nausea.

abdominal pain. There have been reports of multiple congenital abnormalities in infants whose mothers were being treated for 3 or more months with high dose (400-800mg/day) fluconazole. Fluconazole is found in human breast milk at concentrations similar to plasma. Therefore,

nursing mothers should limit exposure.

EU Classification

EU Indication of danger: Harmful

> Toxic to Reproduction: Category 2 Dangerous for the Environment

EU Hazard Symbols:



EU Risk Phrases:

Material Name: DIFLUCAN® (Fluconazole) capsules

Revision date: 13-Jul-2011 Version: 3.0

2. HAZARDS IDENTIFICATION

R22 - Harmful if swallowed.

R61 - May cause harm to the unborn child. R64- May cause harm to breastfed babies.

R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic

Page 2 of 8

environment.

Australian Hazard Classification

(NOHSC):

Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Silica colloidal, Ph. Eur.	112945-52-5	Not Listed	Not Listed	*
Fluconazole	86386-73-4	Not Listed	Xn;R22 Repr.Cat.2;R61 R64 R52/53	42.5
Corn Starch	9005-25-8	232-679-6	Not Listed	*
Sodium lauryl sulfate	151-21-3	205-788-1	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Lactose	63-42-3	200-559-2	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

Material Name: DIFLUCAN® (Fluconazole) capsules Page 3 of 8
Revision date: 13-Jul-2011 Version: 3.0

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fine / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken,

avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or

environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other

equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Silica colloidal, Ph. Eur.

Austria OEL - MAKs 4 mg/m³

Fluconazole

Pfizer OEL TWA-8 Hr: 500µg/m³

Corn Starch

ACGIH Threshold Limit Value (TWA)

Australia TWA

Belgium OEL - TWA

10 mg/m³

10 mg/m³

10 mg/m³

10 mg/m³

10 mg/m³

40 mg/m³

Czech Republic OEL - TWA

4.0 mg/m³

Material Name: DIFLUCAN® (Fluconazole) capsules Page 4 of 8
Revision date: 13-Jul-2011 Version: 3.0

voicion.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

 Greece OEL - TWA
 10 mg/m³

 5 mg/m³
 10 mg/m³

 Ireland OEL - TWAs
 10 mg/m³

 OSHA - Final PELS - TWAs:
 15 mg/m³

 Portugal OEL - TWA
 10 mg/m³

 Portugal OEL - TWA
 10 mg/m³

 Slovakia OEL - TWA
 4 mg/m³

 Spain OEL - TWA
 10 mg/m³

Sodium lauryl sulfate

Pfizer OEL TWA-8 Hr: 0.3 mg/m³

Magnesium stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWAs 5 mg/m³

Analytical Method: Analytical method available for Fluconazole. Contact Pfizer Inc for further information.

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:CapsuleColor:WhiteMolecular Formula:MixtureMolecular Weight:Mixture

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Page 5 of 8

Material Name: DIFLUCAN® (Fluconazole) capsules

Revision date: 13-Jul-2011 Version: 3.0

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Lactose

Rat Oral LD50 > 10 g/kg

Sodium lauryl sulfate

Rat Oral LD50 1288 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m³

Fluconazole

Rat (F) Oral LD50 1575 mg/kg
Rat (M) Oral LD50 1325 mg/kg
Mouse Oral LD50 1410 mg/kg
Mouse (M) Oral LD50 1520 mg/kg
Dog Intravenous LD50 > 100 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium lauryl sulfate

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild Moderate
Skin Sensitization - GPMT Guinea Pig Negative
Skin Sensitization - LLNA Mouse Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Fluconazole

3 Month(s) Rat Oral 5 mg/kg/day NOAEL Liver 6 Month(s) Dog Oral 7.5 mg/kg/day NOAEL Liver 12 Month(s) Rat Oral 10 mg/kg/day LOAEL Liver 12 Month(s) Dog Oral 2.5 mg/kg/day NOAEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Fluconazole

Reproductive & Fertility Rat Oral 20 mg/kg/day NOAEL Negative

Embryo / Fetal Development Rabbit Oral 20 mg/kg/day NOAEL Maternal Toxicity, Not Teratogenic

Embryo / Fetal Development Rat Oral 5 mg/kg/day NOAEL Fetotoxicity, Maternal Toxicity

Embryo / Fetal Development Rat Oral 80 mg/kg/day LOAEL Maternal Toxicity, Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sodium lauryl sulfate

Bacterial Mutagenicity (Ames) Salmonella Negative

F04

Material Name: DIFLUCAN® (Fluconazole) capsules

Revision date: 13-Jul-2011 Version: 3.0

11. TOXICOLOGICAL INFORMATION

Fluconazole

In Vitro Bacterial Mutagenicity (Ames) Salmonella , E. coli Negative

In Vivo Cytogenetics Mouse Bone Marrow Negative In Vitro Cytogenetics **Human Lymphocytes** Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Fluconazole

24 Month(s) Rat Female Oral 10 mg/kg/day NOAEL Not carcinogenic 24 Month(s) Rat Female Oral 5 mg/kg/day LOEL Benign tumors, Liver

24 Month(s) mg/kg/day NOEL Not carcinogenic

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. Carcinogen Status:

See below

Silica colloidal, Ph. Eur.

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:

The environmental characteristics of this mixture have not been fully evaluated. Harmful effects to aquatic organisms could occur. Releases to the environment should be avoided.

Page 6 of 8

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Sodium lauryl sulfate

Oncorhynchus mykiss (Rainbow Trout) LC50 96 Hours 3.6 mg/L

Fluconazole

Daphnia magna (Water Flea) LC50 48 Hours 35 mg/L Pimephales promelas (Fathead Minnow) LC50 > 50 mg/LCyprinodon variegatus (Sheepshead Minnow) LC50 > 50 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum

solubility. Since the substance is insoluble in aqueous solutions above this concentration, an

acute ecotoxicity value (i.e. LC/EC50) is not achievable.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Material Name: DIFLUCAN® (Fluconazole) capsules Page 7 of 8

Revision date: 13-Jul-2011 Version: 3.0

15. REGULATORY INFORMATION

EU Symbol:

EU Indication of danger: Harmful

Toxic to Reproduction: Category 2 Dangerous for the Environment

EU Risk Phrases:

R22 - Harmful if swallowed.

R61 - May cause harm to the unborn child. R64- May cause harm to breastfed babies.

R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

EU Safety Phrases:

S22 - Do not breathe dust.

S36 - Wear suitable protective clothing.

S53 - Avoid exposure - obtain special instructions before use.

S57 - Use appropriate containment to avoid environmental contamination.

OSHA Label:

WARNING

Harmful if swallowed.

Suspected of damaging the unborn child. May cause harm to breastfed babies.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Silica colloidal, Ph. Eur.

Australia (AICS): Present

Fluconazole

Standard for the Uniform SchedulingSchedule 3for Drugs and Poisons:Schedule 4

Corn Starch

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present

Material Name: DIFLUCAN® (Fluconazole) capsules Page 8 of 8
Revision date: 13-Jul-2011 Version: 3.0

15. REGULATORY INFORMATION

REACH - Annex IV - Exemptions from the Present

obligations of Register:

EU EINECS/ELINCS List 232-679-6

Sodium lauryl sulfate

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentStandard for the Uniform SchedulingSchedule 6

for Drugs and Poisons:

EU EINECS/ELINCS List 205-788-1

Lactose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

Present

obligations of Register:

EU EINECS/ELINCS List 200-559-2

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
209-150-3

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.

R61 - May cause harm to the unborn child. R64 - May cause harm to breastfed babies.

R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 5 - Fire Fighting Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls

/ Personal Protection. Updated Section 15 - Regulatory Information.

Prepared by: Product Stewardship Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
